Skip to content
ApprovedFDA approvedStrong evidence

Pregabalin

Prescription anti-anxiety and nerve-pain medicine that can cause physical dependence.

AnxiolyticGabapentinoidAnticonvulsantGabapentinoidAnxiolyticGABAGlutamatenoo.affects.anxiety
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassGabapentinoid · Anxiolytic
Primary targetα2δ-1 voltage-gated calcium channel subunit
Targets4 receptor targets
Half-lifeAbout 6 hours (excreted essentially unchanged via the kidneys)
OnsetFor anxiety the effect typically appears within 1 week; dosed once or twice daily
EvidenceStrong evidence
Affected systemsGABAGlutamatenoo.affects.anxiety

Contents

DETAILED OVERVIEW

What is Pregabalin?

Pregabalin (Lyrica) is a prescription medicine. In the European Union, including Hungary, it is approved for generalized anxiety disorder, nerve-related (neuropathic) pain and as add-on treatment for epilepsy. In the United States it is approved for pain and epilepsy, and it is a controlled substance because of its risk of misuse.

Its structure resembles GABA, the brain's main calming messenger, but it does not act on GABA receptors. Instead it acts on the calcium channels of nerve cells, which calms overactive signaling. In studies it often eased anxiety within the first week. Drowsiness and dizziness can occur as side effects, especially in the first weeks of treatment. It can cause physical dependence, and stopping it suddenly can bring withdrawal symptoms (anxiety, sleep problems, nausea). Together with opioids, other sedatives or alcohol, it increases sedation and dangerously slows breathing.

Mechanism

α2δ-1 calcium channel ligand

Half-life

About 6 hours

Legal status

Prescription drug (EU: approved for GAD)

Receptor profile

  • α2δ-1 calcium channel subunitStrong
  • Glutamate and noradrenaline release (reduces)Moderate
  • Substance P releaseModerate
  • GABA receptors (no direct binding)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Drowsiness, dizziness and sedation, especially in the first weeks of treatment
  • Cognitive clouding, difficulty concentrating, blurred vision
  • Weight gain, peripheral oedema (limb swelling), dry mouth
  • Euphoria and mood elevation: potential for recreational misuse
  • Physical dependence: withdrawal syndrome on abrupt cessation (anxiety, insomnia, sweating, nausea)
  • Increased risk of respiratory depression when combined with opioids or other sedatives

Contraindications · 5

  • Impaired kidney function: dose must be reduced according to creatinine clearance
  • History of substance use disorder: heightened misuse and dependence risk
  • Concurrent opioids, benzodiazepines or alcohol: additive sedation and respiratory depression
  • Pregnancy and breastfeeding: only after clear benefit-risk assessment under medical supervision
  • Do not stop abruptly: treatment should be tapered gradually over at least one week

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Pregabalin is a prescription medication used mainly for anxiety disorders, working by calming overactive nerve signaling through a specific calcium-channel protein. Studies show it often eases both the mental and physical symptoms of anxiety within the first week, with a strength comparable to benzodiazepines but through a different mechanism. It's also effective for neuropathic pain and fibromyalgia, conditions where pain and anxiety frequently overlap, and it can help as an add-on for patients who don't respond fully to SSRI/SNRI antidepressants alone.

Telegram

Have a question about Pregabalin?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeAnxiolytic
FormulaC8H17NO2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.